Premium
ABCB 1‐1Δ (MDR1‐1Δ) genotype is associated with adverse reactions in dogs treated with milbemycin oxime for generalized demodicosis
Author(s) -
Barbet Joy L.,
Snook Tara,
Gay John M.,
Mealey Katrina L.
Publication year - 2009
Publication title -
veterinary dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.744
H-Index - 60
eISSN - 1365-3164
pISSN - 0959-4493
DOI - 10.1111/j.1365-3164.2008.00725.x
Subject(s) - genotype , medicine , ivermectin , adverse effect , demodicosis , adverse drug reaction , ataxia , veterinary medicine , gastroenterology , anesthesia , pharmacology , biology , dermatology , drug , genetics , psychiatry , gene
Twenty‐two dogs diagnosed with generalized demodicosis were treated with milbemycin oxime (MO) because of poor response to previous therapies or because the dog was a breed known to be susceptible to ivermectin toxicosis. Fifteen of the 22 dogs were herding breeds. Doses of MO ranged from 1.0 to 2.2 mg kg −1 day −1 per os. Cheek swab samples were obtained in order to determine each dog's ABCB 1 genotype. Adverse drug reactions were recorded for each dog by the owners and/or veterinarians. The ABCB 1‐1Δ genotype was significantly associated with the development of an adverse reaction (neurological toxicity) after treatment with MO. None of the 19 dogs with the wild‐type ABCB1 allele experienced adverse reactions, whereas two dogs homozygous for the ABCB1‐1Δ mutation developed ataxia. Assessing the ABCB1‐1Δ genotype prior to MO administration may prevent neurological toxicity in these patients.